A prognostic gene expression index in ovarian cancer - validation across different independent data sets.
GSE14764_eset.Rd
Ovarian carcinoma has the highest mortality rate among gynaecological malignancies. In this project, we investigated the hypothesis that molecular markers are able to predict outcome of ovarian cancer independently of classical clinical predictors, and that these molecular markers can be validated using independent data sets. We applied a semi-supervised method for prediction of patient survival. Microarrays from a cohort of 80 ovarian carcinomas (TOC cohort) were used for the development of a predictive model, which was then evaluated in an entirely independent cohort of 118 carcinomas (Duke cohort). A 300-gene ovarian prognostic index (OPI) was generated and validated in a leave-one-out approach in the TOC cohort (Kaplan-Meier analysis, p = 0.0087). In a second validation step, the prognostic power of the OPI was confirmed in an independent data set (Duke cohort, p = 0.0063). In multivariate analysis, the OPI was independent of the post-operative residual tumour, the main clinico-pathological prognostic parameter with an adjusted hazard ratio of 6.4 (TOC cohort, CI 1.8-23.5, p = 0.0049) and 1.9 (Duke cohort, CI 1.2-3.0, p = 0.0068). We constructed a combined score of molecular data (OPI) and clinical parameters (residual tumour), which was able to define patient groups with highly significant differences in survival. The integrated analysis of gene expression data as well as residual tumour can be used for optimized assessment of the prognosis of platinum-taxol-treated ovarian cancer. As traditional treatment options are limited, this analysis may be able to optimize clinical management and to identify those patients who would be candidates for new therapeutic strategies.
Usage
data( GSE14764_eset )
Format
experimentData(eset):
Experiment data
Experimenter name: Denkert C, Budczies J, Darb-Esfahani S, Gy??rffy B et al. A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol 2009 Jun;218(2):273-80.
Laboratory: Denkert, Lage 2009
Contact information:
Title: A prognostic gene expression index in ovarian cancer - validation across different independent data sets.
URL:
PMIDs: 19294737
Abstract: A 254 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133A] Affymetrix Human Genome U133A Array
platform_shorttitle:
Affymetrix HG-U133A
platform_summary:
hgu133a
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL96
platform_technology:
in situ oligonucleotide
Preprocessing: frma
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1CF A2M ... ZZZ3 (13104 total)
varLabels: probeset gene
varMetadata: labelDescription
Details
assayData: 13104 features, 80 samples
Platform type: hgu133a
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
records n.max n.start events median 0.95LCL 0.95UCL
80.00 80.00 80.00 21.00 4.52 4.19 NA
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Min. 1st Qu. Median Mean 3rd Qu. Max.
1.00 20.75 40.50 40.50 60.25 80.00
sample_type:
tumor
80
histological_type:
Length Class Mode
80 character character
primarysite:
ov
80
summarygrade:
high low
54 26
summarystage:
early late
9 71
tumorstage:
1 2 3 4
8 1 69 2
substage:
a b c NA's
4 6 32 38
grade:
1 2 3
3 23 54
recurrence_status:
norecurrence recurrence NA's
50 26 4
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
210 660 1050 1011 1328 2190
vital_status:
deceased living
21 59
batch:
Length Class Mode
80 character character
uncurated_author_metadata:
Length Class Mode
80 character character